Market Survey on Gabapentin Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Gabapentin Market including Gabapentin as Oral Solution, Gabapentin as Tablet, and Gabapentin as Capsule Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
The gabapentin market is registering a valuation of US$ 2.11 billion in 2023 and is estimated to reach US$ 3.54 billion by 2033. The market is securing a CAGR of 5.3% during the forecast period.
The market has been growing rapidly due to several driving factors, including:
Increasing prevalence of neuropathic pain: As the global population ages, the prevalence of neuropathic pain is expected to increase. It has led to an increased demand for medications like gabapentin that can effectively treat this type of pain.
Growing off-label use: While gabapentin is only approved for certain medical conditions, it has been increasingly prescribed off-label for various conditions. It has led to a significant increase in demand for medication.
Increased awareness and availability: As more people become aware of gabapentin's effectiveness in treating certain conditions, demand for the medication has increased. Additionally, the medication has become more widely available, further contributing to its popularity.
Low cost: Gabapentin is a relatively inexpensive medication compared to other medications used to treat similar conditions. It has made it an attractive option for patients and healthcare providers alike.
Development of new formulations: In recent years, new formulations of gabapentin have been developed that offer improved efficacy and ease of use. It has further contributed to the growth of the gabapentin market.
Attributes
Details
Market CAGR (2023 to 2033)
5.3%
Market Valuation (2023)
US$ 2.11 billion
Market Valuation (2033)
US$ 3.54 billion
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Availability of Alternative Treatments Hinder the Market Growth
Despite the growth drivers, several factors may restrain the market, including:
Side effects: Gabapentin can cause various side effects, including dizziness, drowsiness, and nausea. Sometimes, it can cause more serious side effects, such as suicidal thoughts or behaviors. These side effects can limit its use in certain patient populations and lead to decreased medication demand.
Misuse and abuse: While gabapentin has a low potential for abuse, it has been increasingly misused and abused, particularly in combination with opioids. It has led to concerns about its safety and potential for addiction, which may limit its use and demand.
Patent expiration: The patent for gabapentin has expired, which has led to the development of generic versions of the medication. It has increased competition in the market and led to a decrease in the price of the medication, which may limit its profitability for manufacturers.
Regulatory concerns: The off-label use of gabapentin has led to regulatory concerns, particularly in the United States. The medication has been classified as a controlled substance in certain states. It may limit its use and demand in these areas.
Availability of alternative treatments: There are alternative medications and treatments available for many conditions that gabapentin treats. These alternatives may be more effective or have fewer side effects, which may limit the demand for gabapentin.
Gabapentin Market, 2018 to 2022 Historical Sales, Compared to 2023 to 2033 Future Outlook
According to the FMI report, the global market size was valued at US$ 2.03 billion in 2020 with a CAGR of 4.6%. The increasing prevalence of neurological disorders, such as epilepsy and neuropathic pain, are the primary indications for gabapentin.
Regarding geographic segmentation, North America is expected to dominate the gabapentin market during the forecast period. It can be attributed to the high prevalence of neurological disorders and the presence of leading pharmaceutical companies in the region. Market trends and projections can change rapidly depending on various factors, including competition and technological advances.
Short Term (2023 to 2026): The rising neuropathic pain and disorders are increasing the demand for gabapentinin this time frame. People are more concerned about their health; therefore, for effective treatment, the adoption of gabapentin is rising.
Medium Term (2026 to 2029): The manufacturers are developing several therapies and medications for the patients to maintain their healthy life. These manufacturers are innovating low-cost products with effective advanced technologies to treat patients as per their requirements.
Long Term (2029 to 2033): Growing key players, research & development activities, and new formulations in the healthcare sector for patient recovery. The key companies are adopting several marketing tactics to uplift the market expansion in the coming period. The rising chronic diseases among old age patients around the globe are increasing the adoption of gabapentin.
Find your sweet spots for generating winning opportunities in this market.
Comparative Analysis of Adjacent Markets
Gabapentin Market:
Attributes
Gabapentin Market
CAGR (2023 to 2033)
5.3%
Value (2023)
US$ 2.11 billion
Value (2033)
US$ 3.54 billion
Trends
The rising demand for low-cost treatment with advanced technologies and developments of new formulas.
Opportunities
The government supports growing research & development activities and awareness campaigns by launching new products.
Diabetic Neuropathy Market:
Attributes
Diabetic Neuropathy Market
CAGR (2023 to 2033)
6.9%
Value (2023)
US$ 4.06 billion
Value (2033)
US$ 7.91 billion
Trends
The growing development of an advanced drug to treat diabetic patients and increasing approval of new products.
Opportunities
Changing lifestyle, adopting strategic policies by key players, innovation of advanced treatments, and government initiatives.
Diabetes Care Drug Market:
Attributes
Diabetes Care Drug Market
CAGR (2023 to 2033)
3%
Value (2023)
US$ 55.76 billion
Value (2033)
US$ 74.94 billion
Trends
Increase in chronic diseases, rising health awareness, and several diabetes patients.
Opportunities
Growing development of drug insulin, innovation of new therapies, and availability of co-efficient and high-quality treatments.
The Top Categories Advancing the Global Market are
Capsule Segment Dominate the Global Market
Gabapentin is available in various dosage forms, including capsules, tablets, oral solutions, and extended-release formulations. However, is commonly prescribed form of gabapentin is oral capsules.
According to FMI, the capsule segment dominate the market, accounting for a significant share by 2033. It can be attributed to the ease of administration and accurate dosing provided by capsules and their widespread availability.
Tablets are also a popular dosage form for gabapentin, commonly prescribed for patients who have difficulty swallowing capsules. Oral solutions and extended-release formulations of gabapentin are relatively less common. They may be prescribed in certain cases, such as for patients with difficulty swallowing or requiring a more controlled release of the medication.
Generic Type Segment Leads the Global Market
Gabapentin primarily treats epilepsy and neuropathic pain, including diabetic neuropathy, post-herpetic neuralgia, and trigeminal neuralgia. It is also used off-label for conditions such as anxiety disorders and insomnia.
In terms of type, the gabapentin market is segmented into branded and generic products. The generic segment dominates the market by capturing a significant share by 2033. The availability of several generic drug versions at lower prices leads to increased treatment options.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Analysis of Top Countries in the Market
Growing Advanced Healthcare Facility Drive the United States Market
The market in the United States is significant, with the drug being one of the most widely prescribed medications in the country. Gabapentin is primarily used to treat epilepsy and neuropathic pain. However, it is also prescribed off-label for a range of other conditions, including anxiety disorders and insomnia.
According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020. The report also notes that gabapentin was the country's second-leading prescribed medication for neuropathic pain after pregabalin.
The market in the United States is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. However, branded versions of gabapentin, such as Neurontin, continue to hold a significant market share, particularly for certain indications.
The gabapentin market in the United States is expected to grow in the coming years. Due to the aging population, increasing prevalence of neuropathic pain conditions, and a growing awareness of the drug's efficacy in treating.
Rising Neuropathic Pain Treatment Upsurge the United Kingdom Market Size
The gabapentin market in the United Kingdom is also significant, with the drug being widely prescribed for treating epilepsy and neuropathic pain. Gabapentin is available in various formulations, including capsules, tablets, and oral solutions.
According to a report by the United Kingdom National Health Service, gabapentin was the fourth commonly prescribed medication in 2020. The report also notes that gabapentin was the country's highly prescribed medication for neuropathic pain.
The market in the United Kingdom is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. The branded versions of gabapentin, such as Neurontin, also hold a significant market share.
The United Kingdom has faced increased scrutiny due to concerns about the drug's potential for abuse and addiction. In 2019, gabapentin and pregabalin were reclassified as Class C controlled substances. They are subject to more stringent prescribing and dispensing requirements to reduce the risk of diversion and misuse.
How is Japan Progressing in the Global market?
Japan gabapentin market has been growing steadily in recent years, driven by the increasing prevalence of conditions such as epilepsy and neuropathic pain. Additionally, the availability of generic versions of the drug has made it more affordable and accessible for patients.
Regarding market competition, several domestic and international companies offer generic versions of gabapentin in Japan. These companies include Towa Pharmaceutical Co. Ltd., Nippon Chemiphar Co. Ltd., and Teva Pharmaceutical Industries Ltd. The branded gabapentin, Neurontin, is also available in Japan through Pfizer Japan Inc.
In recent years, the market in Japan has faced challenges related to concerns about the drug's potential for abuse and addiction. It has led to stricter regulations for the prescribing and dispensing of gabapentin and other similar drugs, potentially impacting the market.
Competitive Landscape
The gabapentin market is highly competitive, with many pharmaceutical companies manufacturing and marketing the drug. The market is dominated by generic versions of the drug, which are widely available and often prescribed due to their lower cost. However, branded versions of gabapentin, such as Neurontin, also hold a significant market share.
The key players in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., and Mylan N.V. These companies have a strong presence in the market and offer a range of gabapentin formulations and dosages.
These established players and several emerging pharmaceutical companies are also entering the market, driven by the growing demand for the drug. The companies focus on developing novel formulations and delivery methods for gabapentin, improving patient outcomes, and expanding the market.
Other Essential Players in the Market are:
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Mylan N.V.
Hikma Pharmaceuticals PLC
Zydus Cadila Healthcare Ltd.
Dr. Reddy's Laboratories Ltd.
Lupin Ltd.
Glenmark Pharmaceuticals Ltd.
Apotex Inc.
Amneal Pharmaceuticals Inc.
Torrent Pharmaceuticals Ltd.
Jubilant Life Sciences Ltd.
Cipla Ltd.
Recent Developments in the Market are:
Several key companies, including Pfizer, Teva Pharmaceutical Industries, Mylan, and Hikma Pharmaceuticals are dominating the global market. Here are some recent developments from these companies in the global market:
Pfizer: Pfizer is one of the leading companies in the market. In 2020, Pfizer settled a lawsuit with the state of Oregon for US$ 975,000 over allegations that it engaged in anticompetitive practices to maintain a monopoly over gabapentin. In addition, Pfizer is currently developing a new formulation of gabapentin called PD-217,014, which is being studied for the treatment of neuropathic pain.
Teva Pharmaceutical Industries: Teva is another prominent player in the market. In 2021, Teva announced the launch of a generic version of gabapentin in the United States.
Mylan: Mylan is a global pharmaceutical company that produces a range of medications, including gabapentin. In 2020, Mylan announced the launch of a generic version of gabapentin in the United States
Hikma Pharmaceuticals: Hikma is a multinational pharmaceutical company that produces a range of medications, including gabapentin. In 2020, Hikma announced the launch of a generic version of gabapentin in the United States. The company is also developing a new formulation of gabapentin called HPN-328, which is being studied for treating neuropathic pain.
Scope of Report
Attribute
Details
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Market Analysis
US$ billion for Value
Key Regions Covered
North America, Latin America, The Middle East and Africa, Europe, and Asia Pacific
Key Segments Covered
Dosage Form
Type
Region
Key Companies Profiled
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Mylan N.V.
Hikma Pharmaceuticals PLC
Zydus Cadila Healthcare Ltd.
Dr. Reddy's Laboratories Ltd.
Lupin Ltd.
Glenmark Pharmaceuticals Ltd.
Apotex Inc.
Amneal Pharmaceuticals Inc.
Torrent Pharmaceuticals Ltd.
Jubilant Life Sciences Ltd.
Cipla Ltd.
Report Coverage
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing
Available upon Request
Gabapentin Market by Category
By Dosage Form:
Gabapentin as Oral Solution
Gabapentin as Tablet
Gabapentin as Capsule
By Type:
Gabapentin as Branded
Gabapentin as Generic
Region:
Gabapentin in North America Market
Gabapentin in Europe Market
Gabapentin in Latin America Market
Gabapentin in Asia Pacific Market
Gabapentin in the Middle East Africa Market
Frequently Asked Questions
How big is the Gabapentin market?
The Gabapentin market is valued at US$ 2.11 billion in 2023.
Who are the key Gabapentin market players?
Some of the key players in the Gabapentin market include Pfizer, Sun Pharmaceutical Industries, Mylan, and Teva Pharmaceutical Industries.
Which is the key segment by product type?
Capsules are likely to remain preferred through 2033.
Which is the go-to-market strategy?
Players opt for product launches and partnerships.
Which are the key Asian countries in the Gabapentin Market?
India, Japan, and China dominate the Asian market.
Table of Content
1. Executive Summary | Gabapentin Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
5.3.1. Tablet
5.3.2. Capsule
5.3.3. Oral Solution
5.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Generic
6.3.2. Branded
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
7.3.1. Epilepsy
7.3.2. Neuropathic Pain
7.3.3. Restless Legs Syndrome
7.3.4. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Dosage Form
10.2.3. By Type
10.2.4. By Application
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Dosage Form
10.3.3. By Type
10.3.4. By Application
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Dosage Form
11.2.3. By Type
11.2.4. By Application
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Dosage Form
11.3.3. By Type
11.3.4. By Application
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Dosage Form
12.2.3. By Type
12.2.4. By Application
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Dosage Form
12.3.3. By Type
12.3.4. By Application
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Dosage Form
13.2.3. By Type
13.2.4. By Application
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Dosage Form
13.3.3. By Type
13.3.4. By Application
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Dosage Form
14.2.3. By Type
14.2.4. By Application
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Dosage Form
14.3.3. By Type
14.3.4. By Application
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Dosage Form
15.2.3. By Type
15.2.4. By Application
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Dosage Form
15.3.3. By Type
15.3.4. By Application
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Dosage Form
16.2.3. By Type
16.2.4. By Application
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Dosage Form
16.3.3. By Type
16.3.4. By Application
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Dosage Form
17.1.2.2. By Type
17.1.2.3. By Application
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Dosage Form
17.2.2.2. By Type
17.2.2.3. By Application
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Dosage Form
17.3.2.2. By Type
17.3.2.3. By Application
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Dosage Form
17.4.2.2. By Type
17.4.2.3. By Application
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Dosage Form
17.5.2.2. By Type
17.5.2.3. By Application
17.5.2.4. By Distribution Channel
17.6. United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Dosage Form
17.6.2.2. By Type
17.6.2.3. By Application
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Dosage Form
17.7.2.2. By Type
17.7.2.3. By Application
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Dosage Form
17.8.2.2. By Type
17.8.2.3. By Application
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Dosage Form
17.9.2.2. By Type
17.9.2.3. By Application
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Dosage Form
17.10.2.2. By Type
17.10.2.3. By Application
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Dosage Form
17.11.2.2. By Type
17.11.2.3. By Application
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Dosage Form
17.12.2.2. By Type
17.12.2.3. By Application
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Dosage Form
17.13.2.2. By Type
17.13.2.3. By Application
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Dosage Form
17.14.2.2. By Type
17.14.2.3. By Application
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Dosage Form
17.15.2.2. By Type
17.15.2.3. By Application
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Dosage Form
17.16.2.2. By Type
17.16.2.3. By Application
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Dosage Form
17.17.2.2. By Type
17.17.2.3. By Application
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Dosage Form
17.18.2.2. By Type
17.18.2.3. By Application
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Dosage Form
17.19.2.2. By Type
17.19.2.3. By Application
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Dosage Form
17.20.2.2. By Type
17.20.2.3. By Application
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Dosage Form
17.21.2.2. By Type
17.21.2.3. By Application
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Dosage Form
18.3.3. By Type
18.3.4. By Application
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Zydus Pharmaceuticals, Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Glenmark Pharmaceuticals Limited
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Sun Pharmaceutical Industries Ltd.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Ascend Laboratories, LLC
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Apotex Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Teva Pharmaceutical Industries Ltd.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Aurobindo Pharma
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Amneal Pharmaceuticals LLC.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Cipla USA, Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. BP Pharmaceuticals Laboratories Company
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Assertio Holdings, Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Arbor Pharmaceuticals, Inc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Pfizer Inc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
